Apotex reports a net loss of about $38 million in its first quarter following its initial public offering in June, according to the company’s results covered by Canadian business outlets.
The company says revenue reached about $848 million during the quarter, which it frames as lower than the comparable period in the prior year, when revenue was reported at $1.14 billion. The outlets note the financial decline alongside the timing of the IPO, positioning the quarter as the company’s first public-market reporting period.
While both sources focus on the same headline figures—net loss and revenue—coverage mainly differs in emphasis rather than substance, with some attention on the impact of the year-over-year revenue comparison and the fact the results are tied to the period after the June listing.
